European Solutions
As a specialist niche provider for the clinical, medical and regulatory functions of European life science businesses, Hobson Prior has established an outstanding network of clinical professionals to meet the exacting standards required across the industry sectors we service.
Hobson Prior provides both permanent solutions and interim contract consultancy services throughout Europe, and our approach combines the traditional sourcing methods of file research, advertising, referral and search, to provide the broadest choice possible for each assignment on which we act, and almost always on a contingent, no cure no pay basis.
However our key talent acquisition tool is headhunting with over 50% of successfully completed permanent and interim assignments resulting from the consistent application of our proactive search methodology.
We have successfully completed assignments in the following countries:
| Belgium | Czech Republic | Denmark | Estonia | ||
| Finland | France | Germany | Hungary | ||
| Ireland | Italy | Latvia | Norway | ||
| Poland | Slovakia | Slovenia | Spain | ||
| Sweden | Switzerland | The Netherlands | The UK |
Vacancy Search
Latest News
Anthera listing confirms weak IPO market
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.
